German diagnostics company Qiagen has acquired Genoox, an Israeli provider of AI-powered genetic testing software, in a deal worth US$80 million.

This acquisition aims to enhance Qiagen’s capabilities in clinical testing.

Genoox, founded in 2014, created Franklin, a cloud-based platform that assists small and mid-sized laboratories in analyzing next-generation sequencing (NGS) data.

It is used by over 1,700 healthcare organizations across 50 countries.

The acquisition will integrate Franklin into Qiagen’s Digital Insights portfolio, which also features tools such as QCI Interpret and QCI Precision Insights.

🔗 Source: Calcalist

🧠 Food for thought

1️⃣ Acquisitions reflect rapid growth in genomics services market

Qiagen’s $80 million acquisition of Genoox aligns with broader industry forecasts showing the genomics services market is expected to nearly triple from $8.5 billion in 2024 to $25 billion by 2034, growing at 11.50% annually 1.

This acquisition represents a pattern where established diagnostic companies are strategically expanding their AI and data analysis capabilities through acquisitions rather than building in-house solutions.

The transaction price ($80 million) compared to Genoox’s total funding ($26 million) suggests a healthy multiple, indicating the rising valuation of specialized bioinformatics platforms in the competitive genomics landscape.

Industry data shows next-generation sequencing (NGS) technologies alone generated $2.7 billion in 2023, highlighting why Qiagen would prioritize acquiring tools that streamline NGS data analysis 1.

As the precision medicine market expands toward a projected $103.73 billion by 2035, companies are racing to secure technologies that can efficiently interpret the massive volumes of genomic data being generated 2.

2️⃣ AI becoming essential infrastructure for clinical genetic testing

The acquisition highlights how AI has evolved from experimental technology to critical infrastructure in genomics, with the Genoox platform’s 150,000+ clinical case interpretations demonstrating proven real-world application.

Bioinformatics tools like Franklin address a fundamental challenge in precision medicine: the need for interdisciplinary expertise combining biology and computational sciences to interpret increasingly complex genomic data 3.